2025
Patients with status epilepticus and new‐onset refractory status epilepticus display drastically altered fecal microbiomes compared to chronic epilepsy patients
Steriade C, Thomas S, Xu F, Ahituv A, Hanin A, Pleshkevich M, Hwang S, Ramirez A, Foreman B, Yoo J, Eka O, Kellogg M, Oliger A, Wainwright M, Morales M, Gaspard N, Hirsch L, Devinsky O, Saxena D. Patients with status epilepticus and new‐onset refractory status epilepticus display drastically altered fecal microbiomes compared to chronic epilepsy patients. Epilepsia 2025 PMID: 40387216, DOI: 10.1111/epi.18450.Peer-Reviewed Original ResearchChronic epilepsy patientsSE patientsStatus epilepticusEpilepsy patientsChronic epilepsyPre-existing epilepsyFuture treatment strategiesDisease time pointsInflammatory cytokine levelsFecal microbiomeMicrobiome structureLongitudinal cohort studyMicrobiome featuresCytokine levelsEffective therapyCohort studyTreatment strategiesInflammatory cytokinesSE resolutionInflammatory responseCritical illnessPatientsGut dysbiosisMortality rateClinical treatment
2024
Pharmacologic Inhibition of Transient Receptor Potential Ion Channel Ankyrin 1 Counteracts 2-Chlorobenzalmalononitrile Tear Gas Agent–Induced Cutaneous Injuries
Achanta S, Chintagari N, Balakrishna S, Liu B, Jordt S. Pharmacologic Inhibition of Transient Receptor Potential Ion Channel Ankyrin 1 Counteracts 2-Chlorobenzalmalononitrile Tear Gas Agent–Induced Cutaneous Injuries. Journal Of Pharmacology And Experimental Therapeutics 2024, 388: 613-623. PMID: 38050077, PMCID: PMC10801748, DOI: 10.1124/jpet.123.001666.Peer-Reviewed Original ResearchTransient receptor potential ankyrin 1Tear gas agentsCutaneous injurySkin injuryTRPA1 antagonistTRPA1 inhibitor HC-030031Injury parametersWeek old C57BL/6 male miceInflammatory cytokine levelsC57BL/6 male miceTherapeutic efficacy studiesEffects of CSNeuronal ion channelsMouse ear skinTRPA1 inhibitionAirway obstructionNeurogenic inflammationCytokine levelsHC-030031Severe painPlasma extravasationCS exposureAcute irritationAcute toxic effectsFrequent injuries
2022
CD55 Facilitates Immune Evasion by Borrelia crocidurae, an Agent of Relapsing Fever
Arora G, Lynn GE, Tang X, Rosen CE, Hoornstra D, Sajid A, Hovius JW, Palm NW, Ring AM, Fikrig E. CD55 Facilitates Immune Evasion by Borrelia crocidurae, an Agent of Relapsing Fever. MBio 2022, 13: e01161-22. PMID: 36036625, PMCID: PMC9600505, DOI: 10.1128/mbio.01161-22.Peer-Reviewed Original ResearchConceptsRole of CD55Fever infectionImmune evasionSurface of erythrocytesRosette formationB. crociduraeB. persicaHost factorsBorrelia crociduraeAcute febrile illnessInflammatory cytokine levelsElevated proinflammatory cytokinesExpression of CD55Causative agentErythrocyte rosette formationFacilitates Immune EvasionComplement-mediated lysisHost-pathogen interactionsCytokine levelsFebrile illnessSignificant morbidityProinflammatory cytokinesHigh-throughput screenC5a levelsCD55 expressionMindfulness-based stress reduction may decrease stress, disease activity, and inflammatory cytokine levels in patients with autoimmune hepatitis
Alrabadi LS, Dutton A, Rabiee A, Roberts SJ, Deng Y, Cusack L, Silveira MG, Ciarleglio M, Bucala R, Sinha R, Boyer JL, Assis DN. Mindfulness-based stress reduction may decrease stress, disease activity, and inflammatory cytokine levels in patients with autoimmune hepatitis. JHEP Reports 2022, 4: 100450. PMID: 35434588, PMCID: PMC9011026, DOI: 10.1016/j.jhepr.2022.100450.Peer-Reviewed Original ResearchQuality of lifeMindfulness-based stress reductionInflammatory cytokine levelsDisease activityCytokine levelsAutoimmune hepatitisAlanine aminotransferaseAdult patientsTRIAL REGISTRATIONPeripheral blood cytokine levelsScore improvementMBSR programPilot studyBlood cytokine levelsSerum alanine aminotransferaseClinical trial registrationSignificant dose reductionPerceived stressExploratory pilot studyALT levelsSteroid requirementsStress reductionCytokine mediatorsALT reductionMedication needs
2021
Phase II double blinded randomized placebo-controlled trial of minocycline to ameliorate chemotherapy-induced cognitive changes in breast cancer (BC) patients.
Sharpe J, Schnell P, Knopp M, Binzel K, Magyer M, Cherian M, Gatti-Mays M, Pariser A, Wesolowski R, Sardesai S, VanDeusen J, Stover D, Ramaswamy B, Williams N, DeVries A, Shinde N, Orchard T, Lustberg M. Phase II double blinded randomized placebo-controlled trial of minocycline to ameliorate chemotherapy-induced cognitive changes in breast cancer (BC) patients. Journal Of Clinical Oncology 2021, 39: e12528-e12528. DOI: 10.1200/jco.2021.39.15_suppl.e12528.Peer-Reviewed Original ResearchPET/CT imagingPET/CTCytokine levelsMicroglial activationCT imagingF-fluorodeoxyglucoseDouble-blinded randomized placebo-controlled trialBlinded randomized placebo-controlled trialChemotherapy-induced cognitive changesRandomized placebo-controlled trialCognitive functionPlacebo-controlled trialInflammatory cytokine levelsBreast cancer patientsCognitive changesCT brain imagingAC therapyDaily minocyclinePotent mitigatorNeoadjuvant chemotherapyPlacebo groupInflammatory markersInflammatory changesMedian ageMinocycline group
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply